Inbrija is an FDA-approved inhaled levodopa therapy and is designed to quickly relieve “OFF” episodes in Parkinson’s patients treated with carbidopa/levodopa (when the effects of their regular medication wear off and symptoms begin to return). The medicine is delivered through the lungs rather than the gastrointestinal tract.
Alan Watts, Director, Technology and Innovation – Pulmonary & Nasal at Catalent, a CDMO for pharma and biotech, will be presenting on the manufacturing challenges of scaling this product at the upcoming PharmSci 360, taking place in New Orleans in October. I sat down with him to pick his brain about both the manufacturing and packaging challenges of scaling this inhaled drug.
